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Summary
The angiopoietins comprise a small class of secreted
glycoproteins that play crucial roles in the maturation
and maintenance of the mammalian vascular and lym-
phatic systems. They exert their effects through a
member of the tyrosine kinase receptor family, Tie2.
Angiopoietin/Tie2 signaling is unique among tyrosine
kinase receptor-ligand systems in that distinct angio-
poietin ligands, although highly homologous, can
function as agonists or antagonists in a context-
dependent manner. In an effort to understand this mo-
lecular dichotomy, we have crystallized and deter-
mined the 2.4 Å crystal structure of the Angiopoietin-2
(Ang2) receptor binding region. The structure reveals
a fibrinogen fold with a unique C-terminal P domain.
Conservation analysis and structure-based mutagen-
esis identify a groove on the Ang2 molecular surface
that mediates receptor recognition.
Introduction
The angiopoietins are the secreted ligands of the Tie
family of protein receptor tyrosine kinases (RTK) (Davis
et al., 1996, 2003; Maisonpierre et al., 1997; Ramsauer
and D’Amore, 2002; Valenzuela et al., 1999). Tie2 is one
of a handful of endothelial-specific RTKs that also in-
clude VEGFR. Several groups have shown Tie2 to in-
teract with all four members of the angiopoietin family
(Davis et al., 1996, Valenzuela et al., 1999). Binding
studies have identified the first Ig domain and the three
EGF repeats of Tie2 as essential for angiopoietin bind-
ing (Fiedler et al., 2003).
The four known angiopoietins share significant amino
acid sequence identity and contain a small amino-ter-
minal region that modulates angiopoietin clustering
(superclustering region), followed by a rather large
coiled-coil motif (Davis et al., 1996; Maisonpierre et al.,
1997; Ramsauer and D’Amore, 2002; Valenzuela et al.,
1999). A short linker separates the coiled-coil motif
from a fibrinogen domain at the carboxy terminus.
Binding experiments with Ang1 truncation mutants
have shown that the coiled-coil region is dispensable
for Tie2 binding, although it is responsible for a rather
modest increase in Kd (Davis et al., 2003). It is proposed
that, while the fibrinogen domain is solely responsible*Correspondence: nikolovd@mskcc.org
2 Present address: Institute for Structural Biology and Drug Discov-
ery, Virginia Commonwealth University, 800 East Leigh Street, Suite
212, Richmond, Virginia 23219.for receptor recognition and binding, the coiled-coil
motif mediates homo- or heterodimerization (Davis et
al., 2003; Fiedler et al., 2003; Ward and Dumont, 2002).
While Ang2 can exist as a dimer, both Ang2 and Ang1
are observed primarily as tetramers, hexamers, and
higher-order aggregates in solution (Davis et al., 1996,
2003; Fiedler et al., 2003). Thus, it is thought that the
superclustering region assembles the preformed angio-
poietin coiled-coil dimers into higher-order oligomers.
While Ang1 is a constitutive agonist, Ang2 is a
context-dependent one. It, for example, is incapable of
activating endogenous Tie2 in an endothelial cell cul-
ture system (Maisonpierre et al., 1997). Within this sys-
tem, activation of Tie2 by Ang1 can be competitively
inhibited by Ang2, indicating that they function by act-
ing through the same binding site (Fiedler et al., 2003;
Maisonpierre et al., 1997). This has led to the hypothe-
sis that a general physiological role of Ang2 is to serve
as a competitive antagonist, competing with Ang1 for
Tie2 binding.
In order to gain a more accurate molecular under-
standing of angiopoietin/Tie2 interactions, we deter-
mined the three-dimensional structure of the Ang2 fi-
brinogen-like receptor binding domain (Ang2-RBD) at
2.4 Å resolution. The structure reveals a patch of sur-
face residues conserved within the angiopoietin family
that is likely involved in receptor recognition. Structure-
based mutagenesis and in vitro binding studies corro-
borate the role of this molecular surface in Tie2 binding.
Results
Functional Characterization of the Angiopoietin-2
Receptor Binding Domain
The Ang2 receptor binding domain and the Tie2 ligand
binding domain (Tie2-LBD) were expressed as secreted
Fc-fusion proteins from stably transfected HEK293 cell
lines. To assess the biological activity of our angiopoie-
tin and Tie constructs, we employed several binding
assays. First, gel filtration chromatography was used to
confirm the high-affinity Ang2/Tie2 interaction, in which
we monitored the retention of either Ang2 or Tie2, or a
mixture of the two on an analytical size-exclusion col-
umn. When injected alone, Ang2-RBD elutes with a
retention volume of 17.9 ml corresponding to an ap-
proximate molecular weight of 25 kDa (Figure 1A). Al-
ternatively, Tie2-LBD, when chromatographed alone,
elutes with a retention volume of 15.2 ml and an ap-
proximate molecular weight of 55 kDa (Figure 1B). How-
ever, when Tie2-LBD and Ang2-RBD are injected to-
gether (with Ang2-RBD in slight molar excess), two
peaks are observed with retention volumes of 14.4 ml
(or approximately 70 kDa) and 17.9 ml (or w25 kDa)
(Figure 1C). The first peak at w70 kDa corresponds to
a 1:1 Tie2-LBD/Ang2-RBD complex, while the second
peak corresponds to Ang2-RBD alone. Samples (frac-
tions 12–20) from each run were resolved on SDS-PAGE
and are shown in Figures 1A–1C. Panel (C) clearly il-
lustrates the comigration of Tie2 and Ang2.
Structure
826Figure 1. Gel Filtration Binding Assay Dem-
onstrating Ang2-RBD Functional Activity
(A) Migration of monomeric Ang2-RBD on a
SD-200 column. Ang2-RBD elutes at approx-
imately 25 kDa, as judged by comparison
with molecular weight standards.
(B) Tie2-LBD elutes with an apparent molec-
ular weight of 50 kDa.
(C) Elution of the 1:1 Ang2-RBD/Tie2-LBD
complex at approximately 67 kDa. Note the
large shift in the elution position of Ang2.
The elution positions of molecular weight
standards used to calibrate the column are
shown above.
(D) Sedimentation equilibrium data. The nat-
ural logarithm of the absorbance is plotted
against the square of the radial position.
Data were fit to an ideal single-species
model.We also investigated Ang2/Tie2 complex formation, t
las well as the stoichiometry of the interaction, via ana-
lytical ultracentrifugation. The results of these experi- t
tments are presented in Figure 1D. In agreement with
the results obtained by gel filtration chromatography c
c(Figures 1A–1C) and dynamic light scattering (data not
shown), the analytical ultracentrifugation studies esti- b
imate the molecular weights of Ang2-RBD and Tie2 at
28 kDa and 53 kDa, respectively. In addition, these (
istudies confirm that Ang2-RBD and Tie2 indeed form a
complex with 1:1 stoichiometry (Davis et al., 2003) with a
pan apparent molecular weight of 75 kDa. It should be
noted that, as full-length Ang2 exists either as a dimer t
mor as a multimer of dimers, via interactions mediated
by the coiled-coil and superclustering domains (Davis s
βet al., 2003), the expected stoichiometry of the complex
in vivo would be 2:2 or higher. u
w
tAng2 Structure Determination and Overall
iStructure Description
αThe structure of Ang2-RBD was determined by using a
qcombination of Zn MAD phasing and molecular re-
lplacement (Table 1 and Experimental Procedures) from
gcrystals grown under two distinct conditions. The final
model is refined to an R factor of 22.9% (Rfree of 28.7%)
at 2.4 Å resolution. The structure of the receptor bind- C
Aing fibrinogen-like domain of Ang2 is illustrated in Fig-
ure 2A. Ang2-RBD is a compact, three-domain, mixed t
fα/β protein with overall dimensions of w50Å × 40Å ×
35 Å. The structure is dominated by a large central anti- a
bparallel β sheet packing against four α helices. Ang2-
RBD is structurally most similar to the blood clotting s
cfactor fibrinogen γ chain and the fibrinogen domain of
the horseshoe crab Tachylectin 5A protein (Fiedler et o
cal., 2003; Pratt et al., 1997; Yee et al., 1997; Kairies et
al., 2001). In keeping with the nomenclature of the do- q
fmain architecture of human fibrinogen, we will refer to
the three domains of Ang2-RBD as A, B, and P (red, l
tgreen, and blue, respectively, in Figure 2A). The amino-erminal domain (A) is composed of an α helix (α1), fol-
owed by two β strands (β1 and β2) that both contribute
o the formation of the large central β sheet. There are
hree disulfide bonds connecting residues cys284–
ys313, cys433–cys435, and cys437–cys450. The cys284–
ys313 bond holds α1 against the small β sheet created
y β1 and β2. The second domain (B) is the largest,
ncluding five β strands (β3–β6, β9) and three α helices
α2–α4). The five β strands create a large slightly twist-
ng antiparallel β sheet that is mostly solvent exposed
nd forms a shallow crevice in the outer surface of the
rotein. The three short α helices are inserted in be-
ween strands β3 and β4 and β6 and β7. The third do-
ain (P) contains long, extended coil regions and little
econdary structure, with only two short β strands (β7–
8) and two short α helices (α5–α6). This domain packs
p against the underside of the central β sheet located
ithin the B domain and contains two disulfide bonds
hat serve to position residues involved in calcium bind-
ng and to brace α6 against the loop between β6 and
5. The P domain is the most divergent—both in se-
uence and in structure—among the fibrinogen homo-
ogs, and it is the site of ligand binding for most fibrino-
en domain-containing proteins (see below).
alcium Binding Site
ng2 contains a calcium binding site that is similar to
he one observed in Tachylectin 5A and the C-terminal
ragment of the γ chain of human fibrinogen. Oxygen
toms of two side chains and several main chain car-
onyl oxygens chelate the calcium ion. Specifically, the
ide chains of the conserved Asp429 and Asp431 each
ontribute one interacting oxygen, while the carbonyl
xygen atoms of Cys433 and Cys435 complete the
alcium binding site (Figure 2B). Calcium binding is re-
uired for the proper function of the γ chain of human
ibrinogen. Indeed, a mutation in the calcium binding
oop is responsible for an inherited abnormal fibrinogen
hat exhibits “impaired calcium binding and fibrin poly-
Crystal Structure of Ang2
827Table 1. Summary of Crystallographic Analysis
Crystal Peak Inflection Remote Native F468A/Y474A/Y475A
Resolution (Å) 3.2 3.2 3.2 2.35 2.25
Wavelength (Å) 1.282 1.282 1.255 1.74 0.979
Completeness (%) N/A N/A N/A 97.2 (81.8) 99.9 (100)
Anom. Completeness 92.2 (90.6) 95.7 (92.7) 96.2 (93.2) N/A N/A
(%)
Redundancy (fold) 3.7 4.1 4.1 2.9 3.8
I/σI 13.7 10.9 12.2 9.6 21.1
Rmerge 6.5 8.6 6.9 7.3 4.7
Space group P6122 C2 C2
Cell dimensions (Å) a = b = 94.06, a = 74.19, b = 136.45, c = a = 140.218, b = 94.468, c =
c = 147.73 47.73, β = 93.43 84.673, β = 94.46
Refinement Native F468A/Y474A/Y475A
Resolution (Å) 8.0–2.35 8.0–2.25
Reflections (working/ 17,641/906 48,720/2581
test)
Non-hydrogen atoms 3699 7112
Rcrys/Rfree 22.9/28.7 24.6/27.8
Rmsd
Bonds (Å) 0.007 0.008
Angles (°) 1.57 1.5
Rmerge = Σ|I − <I>|/ΣI, where I = observed intensity, <I> = average intensity obtained from multiple observations of symmetry-related reflections.
Rmsds in bond lengths and angles are the respective rmsds from ideal values.merization” (Koopman et al., 1991). Tachylectin 5A,
which displays agglutinating activity against both
Gram-negative and Gram-positive bacteria, is also de-
pendent upon calcium (Kawabata and Tsuda, 2002). It
is yet unknown what role calcium plays in Ang/Tie2 in-
teractions. Ligand-receptor binding, for example, ap-
pears to be unaffected in the presence of the calcium
chelator EGTA or the divalent chelator EDTA, as mea-
sured by either gel filtration or dynamic light scattering
(data not shown), but such treatments often fail to re-
move protein-ligated calcium ions.
Homology to Other Fibrinogen
Domain-Containing Proteins
Fibrinogen-like domains are interaction modules found
in proteins with diverse binding partners. The structure
of Ang2-RBD can be superimposed on its closest
structural homologs, the fibrinogen domain of Tachy-
lectin 5A and human fibrinogen, with rms deviations of
1.5 Å (208 equivalent Cα positions) and 1.4 Å (210 Cα
positions), respectively (Figures 2C and 2D). The γ chain
of human fibrinogen interacts with the A knob of fibrin
following thrombin cleavage, thereby promoting fibrin
polymerization, while Tachylectin 5A is a lectin involved
in the innate immune response in the Japanese horse-
shoe crab. It is interesting to note that the major struc-
tural differences between these proteins lie within the
P domain, as this is most often the site of ligand in-
teraction (Figure 2D). For instance, the human fibrino-
gen γ chain contains two peptide insertions within the
P domain that serve to create a deep acidic groove that
is involved in binding the thrombin-cleaved α chain N
termini. The carbohydrate binding region in Tachylectin
5A also consists of a hydrophobic pocket that is lined
by tyrosine and histidine aromatic side chains. One side
of this pocket is formed by a loop, which in Ang2 con-
tains a single amino acid insertion, allowing it to adopta unique, Ang2-specific conformation. Although Tachy-
lectin 5A and the γ chain of fibrinogen interact with dis-
tinct ligands, they do share many ligand binding resi-
dues; interestingly, none of these are conserved in the
Ang2 fibrinogen domain.
Identification of the Tie2-Interaction Interface
As discussed above, all fibrinogen domains that are
structurally characterized contain a ligand interaction
site within the P domain, close to the site of calcium
binding. In the case of fibrinogen, this is the site of fi-
brin polymerization, while, for Tachylectin 5A, this is the
site of carbohydrate binding. As residues involved in
receptor binding are likely to be conserved within the
angiopoietin protein family (see Figure 3A), a close ex-
amination of the Ang2 molecular surface in the context
of sequence conservation could potentially identify re-
gions responsible for Tie2 recognition. Figure 3B il-
lustrates the molecular surface of Ang2-RBD colored
according to sequence conservation. Regions colored
in red are 100% conserved among all four angiopoietin
family members, while regions in blue, green, and white
are only 75%, 50%, or 25%-or-less conserved. The lo-
cation of the ligand binding site in the fibrinogen do-
mains of Tachylectin 5A and human fibrinogen is
marked by a yellow circle. This region in Ang2 appears
to be highly conserved (indicated by the blue and red
coloring), and we postulate that it likely includes the
molecular determinants involved in receptor recogni-
tion and binding. Interestingly, the patch highlighted in
Figure 3B contains residues that are not conserved
among the structurally related, but functionally distinct,
angiopoietin-like proteins. The angiopoietin-like pro-
teins are similar in overall domain architecture to angio-
poietins, yet have an overall lower sequence identity
and do not interact with Tie2 (Maisonpierre et al., 1997).
To investigate the role of the conserved patch in the
Structure
828Figure 2. Structure of Ang2-RBD
(A) The refined model of Ang2-RBD with
each of the three domains shown in a dif-
ferent color. The black sphere represents the
bound calcium ion.
(B) A 2Fo − Fc calcium-omit map (blue) con-
toured at 1.5 σ depicting the clear region of
density occupied by the bound calcium ion.
The refined model is shown in ball-and-stick
format with nitrogens in blue, carbons in yel-
low, oxygens in red, and sulfurs in green.
(C) Side-by-side alignment of the Ang2
structural homologs Tacylectin 5A bound to
N-acetyl glucosamine (PDB ID 1JC9) and
the γ chain of human fibrinogen bound to the
gly-pro-arg-pro peptide (PDB ID 2FIB). The
ligands are shown in ball-and-stick format.
(D) Stereoview of Ang2-RBD (red) superim-
posed on Tachylectin 5A (blue) and the γ
chain of human fibrinogen (green). The black
sphere represents the bound calcium ion in
space-filling format.P domain, we mutated several residues within this re- o
tgion, including K467, F468, K472, Y474, and Y475, as
well as two residues that lie in a nonconserved surface Y
cregion (K371E and H373A). Three Ang2 mutants were
created by combining K467E and K472E into one, r
dF468A, /Y474A, and/Y475A into a second, and K371E
and H373A into a third. Gel filtration binding assays
f(Figures 4B and 4D) confirm that mutations made within
the conserved region lead to a protein incapable of 3
mbinding Tie2, while the mutations within the noncon-
served Ang2 region do not affect Tie2 binding (see also t
Ibelow, data not shown for the K371E/H373A mutant).
As all of these mutations are in surface-exposed resi- T
adues, they likely do not affect the overall folding of the
protein. To confirm this, we crystallized and determined A
othe structure of the F468A/Y474A/Y475A mutant at
2.25 Å resolution. As expected, the overall structure is t
(very similar to that of the wild-type protein (Figure 5).
The rmsd between the two structures is 0.8 Å, and the wnly significant difference occurs within the helix con-
aining residues Y475 and Y474. Within the F468A/
474A/Y475A mutant, α6 adopts a slightly different
onformation and packs at a somewhat altered angle
elative to the main β sheet created within the B
omain.
Interestingly, the angiopoietins contain two other sur-
ace patches of particularly conserved residues (Figure
B, between the two arrows), suggesting that these
ight also be involved in biologically important interac-
ions. Furthermore, the observation that both the first
g domain and the following three EGF repeats of the
ie2 receptor are required for Ang2 binding (Fiedler et
l., 2003) suggests that the Tie2-interacting region of
ng2 might be quite large and include surfaces outside
f the P domain. To test this hypothesis, we generated
wo Ang2 mutants, I296A/T298A and R336A/E340A
Figure 3A, black dots), which alter conserved regions
ithin the A and B domain, respectively. In vitro binding
Crystal Structure of Ang2
829Figure 3. Sequence Conservation of the Re-
ceptor Binding Domain among Angiopoietin
Family Members
(A) Sequence conservation among the four
angiopoietins within the receptor binding
domain. Regions of sequence identity to
Ang2 are indicated. Secondary structure ele-
ments are noted above. Black triangles re-
present the conserved aspartic acids in-
volved in calcium chelation. Red asterisks
indicate residues involved in receptor re-
cognition identified in this study. Black cir-
cles indicate residues within the conserved
regions of the A and B domains that were
also subject to mutagenesis, but found not
to be involved in receptor recognition. The P
domain is boxed in green.
(B) Sequence conservation mapped onto the
molecular surface of Ang2-RBD. Secondary
structure renderings are shown below each
surface representation to orient the reader.
Absolutely conserved residues (100%) are
shown in red; partially conserved residues
(75% or 50%) are shown in blue and green,
respectively. Surfaces in gray represent resi-
dues that are not conserved among angio-
poietin family members. The three views are
related by 180° rotation along the y axis (left)
and 90° rotation along the x axis.
Structure
830Figure 4. Gel Filtration Receptor Binding Analysis of Ang2 Mutants
(A and C) The mutants elute as monomers on gel filtration chromatography with estimated molecular weights similar to that of the wild-
type protein.
(B and D) The F468A/Y474A/Y475A and K467E/K472E mutants, located within the P domain of Ang2, do not bind Tie2. The elution positions
of the molecular weight standards used to calibrate the column are shown above.
(E) The structure of Ang2-RBD indicating the location of residues (ball-and-stick format) within the P domain involved in receptor recognition
in yellow (aromatic residues) and purple (basic residues).
(F and G) Mutations within the conserved surface regions of the A domain (I296A/T298A) and the B domain (R336A/E340A) do not affect
receptor binding.experiments (Figures 4F and 4G) document that the mu- D
tated Ang2-RBD proteins are still able to form stable
complexes with Tie2, indicating that these conserved mo- F
ulecular surfaces are not involved in receptor recognition.
Instead, they could be involved, for example, in interac- m
ltions between angiopoietin monomers, as they are nor-
mally dimerized by the coiled-coil domain in the full- c
wlength molecule. As with the proposed Tie2-interaction
surface within the P domain, the surfaces within the A d
mand B domains are conserved only in the angiopoietins,
but not in the other fibrinogen-like proteins. ciscussion
ibrinogen domains function as molecular recognition
nits with a diverse array of binding partners. Indeed,
any of the fibrinogen domain-containing proteins are
ectins, but there are also several protein-protein re-
ognition examples, including the fibrinogen γ chain as
ell as the angiopoietins. It appears that the variable P
omain has evolved to serve as a ligand-recognition
odule as elucidated by crystal structures of the γ
hain of fibrinogen in complex with a peptide derived
Crystal Structure of Ang2
831Figure 5. Structure of the F468A/Y474A/Y475A Ang2-RBD Mutant
The structure is (blue) superimposed on the structure of the wild-
type protein (red). Mutated residues are shown in yellow ball-and-
stick format.from the α chain, and of Tachylectin 5A in complex with
GlcNac. Our data presented here provide evidence that
Angiopoietin-2, another fibrinogen domain-containing
protein, utilizes the variable P domain for receptor bind-
ing. Indeed, two cluster mutations within this region
completely abolish receptor binding. In addition, con-
servation analysis of the angiopoietin family members
projected onto the three-dimensional structure suggests
that other surface regions within the B domain also pos-
sess important, but distinct, biological functions.
It is noteworthy that many of the fibrinogen domain-
containing proteins exist as multimers in vivo. Angio-
poietin-2 is no exception, as the initial Ang1 and Ang2
dimers are further assembled in tetramers, hexamers,
and higher-order complexes. In light of the location of
the P domain within Ang2, our structure suggests that,
upon dimer formation (mediated via coiled-coil motif in-
teractions), the P domains would be oriented away from
the dimerization interface, facilitating the simultaneous
binding of two Tie2 receptors for signaling initiation.
The Ang2 structure identifies a metal binding site that
is structurally conserved among fibrinogen domain-
containing proteins. The close proximity of the calcium
site to the receptor binding region indicates that the
function of the metal ion is to stabilize the local struc-ture for receptor binding. Indeed, calcium is likely re-
quired to keep the pocket architecturally intact and
thereby accessible to receptor contact. Interestingly, al-
though EGTA does not inhibit the Ang2/Tie2 interac-
tions, several mutations in Ang2 designed to disrupt
calcium chelation led to highly unstable proteins and
very low expression (data not shown), indicating that
Ca2+ is required for angiopoietin stability and function.
The crystal structure of an angiopoietin represents an
advance in our understanding of the molecular mecha-
nisms of Ang/Tie2 signaling and provides a solid foun-
dation for future structural, biochemical, and cell-based
studies aimed at understanding the molecular basis of
the context-dependent antagonism demonstrated by
this unique receptor/ligand system.
Experimental Procedures
Expression, Purification, and Mutagenesis
Ang2-RBD (amino acids 276–496) and Tie2-LBD (amino acids 1–
448) were cloned as IgG fusions into a modified pcDNA3.1 vector
(Invitrogen) for constitutive expression in human embryonic kidney
293 (HEK293) cells. Carboxy-terminal to the gene of interest, we
placed a thrombin cleavage site followed by the constant domain
of IgG to facilitate protein purification. Following clarification of the
media from stable transformants, the fusion protein was purified by
affinity chromatography with Protein-A Sepharose and was cleaved
with thrombin. The following nine vector-derived amino acids re-
main at the C terminus of Ang2 following thrombin cleavage:
GSASGLVPR. The cleaved fusion tag was removed by Protein-A
Sepharose, and the proteins were further purified by gel filtration
chromatography. N-terminal sequencing confirmed the identity of
the purified products. The Tie2 receptor was expressed and di-
rected for secretion by using the native signal sequences, while
the fibrinogen domain of Angiopoietin-2 was secreted by using the
efficient CD5 signal sequence. Typical expression levels were 5–10
mg per liter of culture. Site-directed mutants were prepared by
using the Quikchange mutagenesis kit (Stratagene) following the
manufacturers suggestions. Double- and triple-substitution muta-
tions (rather than single substitutions) were designed and gener-
ated in order to create a larger change in the chemical nature of
the targeted surfaces. While most mutations were to alanines,
some lysines were mutated to glutamic acids in order to alter the
local surface electrostatic potential.
Size-Exclusion Chromatography and Equilibrium
Sedimentation Assays
Purified proteins were mixed at 20 M in a buffer containing 20 mM
HEPES (pH 7.4), 200 mM NaCl (HBS) and were incubated for 1 hr
on ice prior to analysis. For gel filtration, 500 l was injected onto
a Superdex-200 column (10/30) (Pharmacia) preequilibrated in 20
mM HEPES (pH 7.4), 200 mM NaCl. Fractions (1 ml) were collected
and resolved on SDS-PAGE.
For the analytical ultracentrifugation experiments, 10 M protein
solution was loaded in HBS and centrifuged at 20°C and 14,000
rpm in a Beckman XL-A ultracentrifuge equipped with an An-60Ti
rotor. Data were fit to an ideal single-species model of absorbance
versus radial distance, and they showed no systematic depen-
dence of molecular weight on protein concentrations.
Crystallization, Data Collection, and Structure Determination
Ang2-RBD was concentrated to 15 mg/ml in a buffer containing 20
mM bis-Tris propane (pH 7.0) and 200 mM NaCl. The protein was
crystallized in a hanging drop by vapor diffusion at room temper-
ature (20°C). Two crystal forms suitable for diffraction studies were
obtained: one against a reservoir containing 5 mM zinc sulfate, 100
mM MES (pH 6.25), and 22% PEG-550, and another against a res-
ervoir containing 0.2 M MgCl2, 100 mM Tris (pH 8.5), and 30%
PEG-4000.
Structure
832Crystals grown in the presence of zinc were harvested and flash C
Bfrozen in the cold stream of an X-Stream cooling system in the
mother liquor with 30% PEG-550 as a cryoprotectant, while crys- D
tals grown in the presence of PEG-4000 were rapidly transferred to J
a cryo-buffer consisting of the mother liquor with an additional 20% a
glycerol. The data were collected at NSLS Brookhaven beamline f
X9A and CHESS beamline F2. Oscillation photographs were integ- 1
rated, merged, and scaled by using DENZO and SCALEPACK, D
respectively (Otwinowski and Minor, 1997). Subsequent calcula- a
tions were done with autoSHARP and the CCP4 program suite e
(CCP4, 1994; Evans and Bricogne, 2002). The structure was deter- f
mined with a combination of MAD phasing and molecular replace- B
ment. Initially, the program AMORE was used to identify the loca-
Etion of the fibrinogen domain by using the horseshoe crab
cTachylectin 5A (PDB ID 1JC9) as a search model (Fiedler et al.,
i2003; Jones et al., 1991). Simultaneously, a zinc anomalous data
Aset was collected by utilizing a single zinc atom involved in mediat-
Fing an intermolecular crystal contact. The program autoSHARP
Mwas used to identify the location of the zinc atom and to refine its
pposition and occupancy for phase calculations. Density modifica-
ttion with DM improved the zinc MAD maps that proved to be of
gsufficient quality to confirm the placement of the fibrinogen domain
(CCP4, 1994). The model was subjected to 100 rounds of improve- J
ment in the program ARP/wARP by using the phases calculated p
by autoSHARP and phase constraints with a blurring factor of 1.0 m
(Perrakis et al., 2001). Refinement proceeded with iterative rounds 4
of model adjustments (by using the molecular graphics program K
O), molecular dynamics, and energy minimization in CNS (Brunger n
et al., 1998; Jones et al., 1991). The first model was refined at 3.2 Å c
resolution to R and Rfree values of 26.9 and 32.8, respectively, for m
1725 atoms and 215 amino acids. t
At this point, crystals grown from MgCl2 and PEG that diffracted Kto a higher resolution were identified. The high-resolution structure
rwas determined by using molecular replacement with the zinc
AAng2-RBD structure as a search model. The model was subjected
Kto adjustments with O and refined in CNS. Stereochemical analysis
gof the refined models with PROCHECK (CCP4, 1994) revealed main
tchain and side chain parameters better than or within the typical
frange of values for protein structures.
The F468A/Y474A/Y475A mutant was crystallized from 0.2 M am- M
Smonium sulfate, 0.1 M sodium acetate (pH 5.2), 22% PEG-4000.
Crystals were transferred to mother liquor with 20% glycerol for p
fflash freezing. A 2.25 Å native data set was collected at CHESS
beamline F2. The CCP4 program AMORE was used to locate four O
monomers in the asymmetric unit. In an attempt to keep the model t
unbiased within the loop containing the mutations, residues 467– 3
476 were omitted in the initial model. The model was subsequently P
subjected to additional rounds of refinement within the CNS suite A
prior to manually building the missing region by using the graphical C
program O.
P
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